CELEX: 62016TN0080
Language: en
Date: 2016-02-23 00:00:00
Title: Case T-80/16: Action brought on 23 February 2016 — Shire Pharmaceuticals Ireland v EMA

18.4.2016   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 136/37
            
         Action brought on 23 February 2016 — Shire Pharmaceuticals Ireland v EMA
   (Case T-80/16)
   (2016/C 136/52)
   Language of the case: English
   
      Parties
   
   
      Applicant: Shire Pharmaceuticals Ireland Ltd (Dublin, Ireland) (represented by: D. Anderson, QC, M. Birdling, Barrister, G. Castle and S. Cowlishaw, Solicitors)
   
      Defendant: European Medicines Agency
   
      Form of order sought
   
   The applicant claims that the Court should:
   
               —
            
            
               annul the decision of the European Medicines Agency dated 15 December 2015 and communicated to the applicant on 18 December 2015 refusing to validate an application pursuant to Regulation (EC) No 141/2000 (1) for designation as an orphan medicinal product; and
            
         
               —
            
            
               order the defendant to pay the applicant’s costs.
            
         
      Pleas in law and main arguments
   
   In support of the action, the applicant relies on one plea in law, alleging that the contested decision erred in its interpretation and application of Regulation (EC) No 141/2000. The applicant contends that the defendant:
   
               —
            
            
               misapplied Article 5 of Regulation (EC) No 141/2000 by failing to appreciate the procedural nature of the validation process;
            
         
               —
            
            
               should not have concluded that the conditions for designation were not (or could not be) established;
            
         
               —
            
            
               erroneously elided the concepts of ‘medicinal product’ and ‘active substance’ contrary to Articles 3 and 5 of Regulation (EC) No 141/2000;
            
         
               —
            
            
               misapplied and erroneously relied upon the communication from the European Commission on Regulation (EC) No 141/2000 (2);
            
         
               —
            
            
               erroneously placed reliance on the fact that the applicant had previously received protocol assistance pursuant to Article 6 of Regulation (EC) No 141/2000; and
            
         
               —
            
            
               frustrated the objective of Regulation (EC) No 141/2000 as identified by Article 1 of Regulation (EC) No 141/2000 and its recitals.
            
         
      (1)  Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ 2000 L 18, p. 1).
   
      (2)  Communication (2003/C 178/02) from the Commission on Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products (OJ 2003 C 178, p. 2).